Azenta (AZTA) just dropped a dense update that combined fourth quarter and full year results, fresh revenue guidance for fiscal 2027, and confirmation that a sizable share repurchase program has wrapped up.
Revenue for the quarter and the year landed higher than the prior period, while quarterly profit shrank and the latest fiscal year closed with a much wider loss. At the same time, management outlined expected top line ranges for the coming year and detailed how almost 10% of the share count was bought back, giving investors several moving parts to weigh at once.
Azenta’s earnings release and buyback update landed after a sharp shift in sentiment, with the share price logging a 30-day share price return of 33.91% and a 90-day share price return of 35.94%. The 1-year total shareholder return of 53.45% contrasts with a 5-year total shareholder return that declined 61.78%, pointing to strong recent momentum on the back of fresh guidance and capital returns, but a much weaker longer run for investors who have held through earlier years.
Compare Azenta’s sharp sentiment shift with a curated group of other potential rebound and value plays using our 34 high quality undervalued stocks.
A sharp 1 year rebound, a completed buyback, and a recent loss on the income statement put Azenta in an awkward spot. Does it make more sense to commit at today’s price or wait for a cooler entry?
Azenta closed at $45.65 compared with the analyst consensus Narrative fair value of $37.80. Based on this, the analyst consensus Narrative on Simply Wall St currently sees the stock as ahead of its estimated worth using an 8.05% discount rate.
Focused capital deployment, including the divestiture of B Medical Systems, the acquisition of UK Biocentre as a European biorepository hub, and active share repurchases, is concentrating Azenta’s portfolio on core life sciences activities and may influence future earnings per share and return on invested capital.
See why 3 investors see Azenta as 21% overvalued.
Result: Fair Value of $37.80 (OVERVALUED)
Still, the bullish Azenta narrative can break if governance issues escalate or if Multiomics softness in North America drags longer than analysts currently build in.
Find out about the key risks to this Azenta narrative.
Analysts on Simply Wall St see Azenta as 20.8% overvalued using their Narrative fair value of $37.80, yet the market is pricing the stock at a P/S of 3.1x. That is in line with its own fair ratio of 3.1x and well below both the US Life Sciences industry on 4.4x and peer companies at 11.5x, which points to less valuation stretch on sales than the earnings based view suggests. Which signal do you trust more: the story built on future profits, or the one anchored to today’s revenue multiple?
See what the numbers say about this price — find out in our valuation breakdown.
If the mixed tone on Azenta leaves you undecided, act promptly, review the underlying numbers, and carefully weigh both the upside and downside using the 2 key rewards and 1 important warning sign.
If Azenta has your attention, do not stop here. The same tools that helped unpack this update can surface other opportunities that might fit your playbook even better.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com